Empagliflozin Market

How big is the empagliflozin market in 2026?

USD 0.6 billion in 2026 and USD 10.4 billion by 2036 at a 33.1% CAGR.

The empagliflozin API market is expected to rise from USD 0.5 billion in 2025 to USD 10.4 billion by 2036. Growth is expected to be driven by regulated formulation demand and wider cardiorenal use. Powder is expected to hold 68.4% share in 2026. The >=99.5% purity grade is estimated to hold 57.2% share in the same year.

Metric	Value
2026 Market Size	USD 0.6 billion
2036 Market Size	USD 10.4 billion
Forecast CAGR (2026-2036)	33.1%
Leading Form	Powder
Powder Share (2026)	68.4%
Leading Purity Grade	>=99.5%
>=99.5% Grade Share (2026)	57.2%
Fastest-growing Country	China
China CAGR by 2036	34.6%

Market Signal	Commercial Impact
Demand and Growth Drivers	Expanding cardiorenal therapy use is sustaining demand for empagliflozin APIs. Diabetes treatment volume keeps baseline API demand active across oral SGLT2 formulation programs. Heart failure labeling creates an additional commercial opportunity for the same active pharmaceutical ingredient. Chronic kidney disease adoption supports longer-term portfolio planning where payers recognize cardiorenal value.
Product and Segment View	Powder form, high-purity grades, and direct sales dominate their respective market segments. Powder is projected to account for 68.4% of 2026 revenue (by form), supported by easier blending during tablet manufacturing. ≥99.5% purity grade is expected to capture 57.2% of 2026 revenue (by purity), reflecting regulatory demand for tighter impurity control. Direct sales are forecast to represent 58.6% of 2026 revenue (by sales channel), driven by audited supplier relationships with large pharmaceutical manufacturers.
Geography and Growth Outlook	China and India are expected to remain the fastest-growing production and consumption markets. China is projected to grow at 34.6% CAGR (2026-2036), supported by expanding disease burden and increasing API manufacturing capacity. India is expected to expand at 33.8% CAGR (2026-2036), driven by rising domestic demand and export-oriented API production.
Competitive Landscape	Competition focuses on API quality, regulatory support, and formulation capabilities. Dr. Reddy’s Laboratories and MetroChem API strengthen their position through established empagliflozin API qualification and regulatory documentation. MSN Laboratories and Lupin enhance competitive intensity with formulation capabilities that influence long-term API sourcing decisions.
Analyst Perspective	Empagliflozin API sourcing is increasingly driven by regulatory confidence rather than pricing alone. Pharmaceutical buyers prioritize suppliers with proven impurity control, stable batch consistency, and comprehensive dossier support. Fast regulatory response and reliable manufacturing records provide suppliers with a stronger competitive advantage. Price competitiveness alone is unlikely to offset weak filing evidence or inconsistent product quality. - Anurag Sharma, Principal Consultant at Future Market Insights (Healthcare)

Quality evidence is becoming the first buying filter in SGLT2 API sourcing because formulation teams verify demand relevance and export readiness before they scale orders. Boehringer Ingelheim reported in March 2026 that JARDIANCE grew 8.7% to EUR 8.8 billion in 2025. CDSCO’s April 2024 WC-0493 certificate lists MetroChem API Unit IV for 27 APIs with manufacturing and packing coverage including Empagliflozin IHS. The same certificate remains valid until January 21 2027. These records are important because small molecule API sourcing moves through documents before commercial orders scale.

Which factors support expansion in the empagliflozin market?

Finished API revenue and regulated filing support are expected to shape market value across diabetes and cardiorenal applications.

• Market value is supported by empagliflozin API revenue before finished-dose brands and pharmacy dispensing are counted.
• Supplier pricing reflects synthesis control and impurity evidence before channel margins affect contract terms.
• Revenue improves as diabetes tablet programs add heart failure and kidney disease planning.
• Buyer trust rises when suppliers provide DMF coverage and clear audit responses.

Why is the empagliflozin market growing?

Regulatory documentation drives API purchasing decisions

Adult diabetes treatment volume gives the market its base. IDF reported 589 million adults with diabetes worldwide in 2024. DailyMed labeling then extends the product role into heart failure and chronic kidney disease. The practical result is stronger demand for high-purity API with complete filing support. Buyers in specialty active pharmaceutical ingredients screen suppliers around documentation before price.

How is the empagliflozin market segmented?

The empagliflozin industry is segmented by form and purity grade. It also covers application, sales channel and region.

• Powder is projected to account for 68.4% share in 2026 because oral solid manufacturers value blend behavior.
• The >=99.5% grade is expected to secure 57.2% share in 2026 as regulated filings need impurity control.
• Type 2 diabetes is forecast to represent 61.5% application share in 2026 through broad oral SGLT2 use.
• Direct sales are anticipated to hold 58.6% share in 2026 because large formulators prefer supplier audits.
• East Asia is expected to hold 31.4% regional share in 2026 due to API capacity and formulation demand.

Why does powder lead the empagliflozin market?

• Powder is projected to account for 68.4% share in 2026 because tablet makers need blend-ready API for oral solid manufacturing.
• Crystalline material remains relevant in stability-sensitive sourcing where buyers compare particle behavior before final processing.

Which purity grade leads the empagliflozin market?

• The >=99.5% grade is expected to hold 57.2% share in 2026 because impurity control affects regulated dossiers.
• Lower-purity grades mainly support early development or less demanding channels before final filing batches are prepared.

Which application leads the empagliflozin market?

• Type 2 diabetes is projected to represent 61.5% share in 2026 because oral antidiabetic therapy provides the largest demand base.
• Heart failure and chronic kidney disease create added portfolio value for the same molecule.

Which sales channel leads the empagliflozin market?

• Direct sales are expected to hold 58.6% share in 2026 because large buyers prefer audited supply contracts.
• Distributors remain useful for sample supply and smaller development batches.

What supports empagliflozin growth and what limits it?

Cardiorenal label expansion supports API demand but filing burden limits weaker suppliers.

• Driver: Diabetes and cardiorenal indications are expected to widen API sourcing across chronic disease portfolios.
• Restraint: Documentation gaps can delay supplier qualification when buyers prepare regulated filings.
• Opportunity: Filing-supported suppliers can win direct contracts as generic formulation windows tighten.

Empagliflozin Market Demand Outlook

Demand outlook is moving toward regulated API supply that can prove impurity control before commercial awards. DailyMed labeling covers adult heart failure and chronic kidney disease risk reduction. EMA product information also gives a 10 mg once-daily dose across type 2 diabetes and cardiorenal uses. Manufacturers serving oral solid dosage formulation should prioritize powder quality and audit-ready documents.

Buyer Segmentation and Purchase Behavior Analysis

The direct buyer is a regulated formulation manufacturer. Large buyers compare API suppliers through batch history and impurity profiles. Smaller buyers may use distributors or online API marketplaces for samples before direct qualification. Demand from obesity-diabetes drugs and GLP-1 diabetes treatment drugs does not remove SGLT2 demand. It raises the need for clear portfolio positioning.

Voice of Customer and Decision-driver Analysis

Formulation buyers are expected to choose suppliers that reduce regulatory friction. A lower API quote loses value when impurity data or audit response is weak. Buyers preparing controlled release or combination products also need partners that understand oral controlled release drug delivery. Documentation quality is therefore a commercial selection factor.

Which countries are growing fastest in the empagliflozin market?

China leads at 34.6% CAGR and India follows at 33.8% CAGR. South Korea records 30.9% and the United States reaches 29.8%. Germany posts 28.4% while France reaches 27.9%. The United Kingdom records 27.6% and Japan reaches 25.8% by 2036.

Country	CAGR
China	34.6%
India	33.8%
South Korea	30.9%
United States	29.8%
Germany	28.4%
France	27.9%
United Kingdom	27.6%
Japan	25.8%

Source: Future Market Insights, 2026.

How do country-level CAGRs compare in the empagliflozin market?

China leads country growth while Japan records the most cautious expansion outlook among profiled markets.

• China is forecast to record 34.6% CAGR by 2036 as disease burden and API capacity support demand.
• India is expected to expand at 33.8% CAGR from 2026 to 2036 through domestic volume and export supply.
• South Korea is projected to grow at 30.9% CAGR through the forecast decade as filing-sensitive buyers qualify suppliers.
• The United States is estimated to rise at 29.8% CAGR by 2036 through FDA-driven product pathways.
• Germany is expected to advance at 28.4% CAGR across the forecast period as quality checks remain strict.
• France is forecast to grow at 27.9% CAGR over the assessment period as reimbursement review shapes access.
• The United Kingdom is projected to post 27.6% CAGR by 2036 as NHS pathways guide prescribing.
• Japan is expected to record 25.8% CAGR during the forecast period as validation cycles slow supplier switching.

How fast is the empagliflozin market growing in China?

A 34.6% CAGR by 2036 reflects country demand conditions and supplier qualification needs.

Country Market Snapshot Table

Parameter	Value
Market Size in 2025 (Value)	USD 85.4 million
Market Size in 2026 (Value)	USD 115.0 million
Market Forecast in 2036 (Value)	USD 2244.6 million
CAGR (2026 to 2036)	34.6%
Years Considered	2021 to 2036
Base Year	2025
Forecast Period	2026 to 2036
Units Considered	Value in USD million
Leading Sub-Region	Yangtze River Delta and Shandong API clusters

China Empagliflozin Market Outlook

China is the largest diabetes demand center in the selected country set. IDF reported 148.0 million adults with diabetes in 2024. Domestic treatment volume and synthesis depth are expected to support a 34.6% CAGR by 2036. Suppliers that pair scale with impurity discipline should be better placed than firms selling only on price.

Commercial demand is expected to favor audited suppliers that can support filings and repeated quality reviews. This makes documentation strength as important as synthesis scale.

Key Growth Drivers

• China demand has a large treatment base since IDF reported 148.0 million adults with diabetes in 2024.
• China cardiorenal planning is supported by EMA product information that gives a 10 mg once-daily dose for chronic kidney disease.
• Chinese API buyers are expected to prioritize suppliers with repeatable impurity records and reliable batch release behavior.
• Export programs can favor suppliers able to answer dossier questions quickly for regulated-market buyers.

Key Restraints

• China demand conversion can lag as WHO reported over 50% of people with diabetes did not take medication in 2022.
• Tender pressure can reduce finished-dose prices and narrow API margin room for weaker suppliers.
• Export acceptance can slow when impurity data or audit records do not satisfy regulated buyers.

What makes China unique

China is unique because disease scale and API synthesis depth support both domestic supply and export screening.

Key Companies

• Zhejiang Huahai Pharmaceutical
• Hansoh Pharma
• CSPC Pharmaceutical Group
• Jiangsu Hengrui Pharmaceuticals
• Qilu Pharmaceutical

Sales & Marketing Channels

• Direct API contracts
• Tender-based formulation supply
• Distributors
• Regulated export channels
• Online API discovery

Country Segment Breakdown Table

Segment	Sub-Segments
By Form	Powder · Crystalline
By Purity Grade	>=99.5% · 98.0%-99.5% · <98%
By Application	Type 2 Diabetes · Heart Failure · Chronic Kidney Disease
By Sales Channel	Direct · Distributors · Online/API Marketplaces
Key Sub-Regions Covered	Shanghai · Jiangsu · Zhejiang · Shandong · Guangdong · Beijing

Frequently Asked Questions

How fast is China empagliflozin market growing?

Demand in China is expected to expand at 34.6% CAGR by 2036 based on local demand and qualification needs.

Who leads China empagliflozin market?

Zhejiang Huahai Pharmaceutical and Hansoh Pharma compete through formulation access. Other local suppliers use quality evidence to gain buyer trust.

What is driving adoption in China empagliflozin market?

Diabetes demand and cardiorenal label use are expected to move buyers toward qualified empagliflozin API suppliers.

What is driving empagliflozin growth in India?

A 33.8% CAGR by 2036 reflects country demand conditions and supplier qualification needs.

Country Market Snapshot Table

Parameter	Value
Market Size in 2025 (Value)	USD 59.8 million
Market Size in 2026 (Value)	USD 80.0 million
Market Forecast in 2036 (Value)	USD 1471.1 million
CAGR (2026 to 2036)	33.8%
Years Considered	2021 to 2036
Base Year	2025
Forecast Period	2026 to 2036
Units Considered	Value in USD million
Leading Sub-Region	Hyderabad and western India API corridors

India Empagliflozin Market Outlook

India combines a large treatment pool with export-oriented API supply. IDF reported 89.8 million adults with diabetes in India in 2024. Domestic demand and regulated export qualification are projected to support a 33.8% CAGR by 2036. Official written confirmation evidence gives buyers a stronger basis for supplier screening.

Commercial demand is expected to favor audited suppliers that can support filings and repeated quality reviews. This makes documentation strength as important as synthesis scale.

Key Growth Drivers

• India demand is supported by diabetes scale since IDF reported 89.8 million adults with diabetes in 2024.
• India API qualification is reinforced by CDSCO written confirmation covering 1 MetroChem API Unit-IV site for Empagliflozin IHS.
• Export programs are expected to favor suppliers with DMF-ready documents and audit-ready production records.
• Formulation companies can combine domestic volume with regulated-market launch planning.

Key Restraints

• India demand conversion can lag as WHO reported over 50% of people with diabetes did not take medication in 2022.
• Domestic pricing pressure can squeeze API margins when finished-dose competition lowers tablet prices.
• Smaller producers may lose regulated buyers when filing documentation is incomplete or dated.

What makes India unique

India is unique because API manufacturing depth and generic formulation capacity operate in the same commercial system.

Key Companies

• Dr. Reddy’s Laboratories
• MetroChem API
• MSN Laboratories
• Lupin
• Zydus Lifesciences
• Aurobindo Pharma

Sales & Marketing Channels

• Direct API contracts
• Contract manufacturing supply
• Domestic formulation buyers
• Export distributors
• Online API marketplaces

Country Segment Breakdown Table

Segment	Sub-Segments
By Form	Powder · Crystalline
By Purity Grade	>=99.5% · 98.0%-99.5% · <98%
By Application	Type 2 Diabetes · Heart Failure · Chronic Kidney Disease
By Sales Channel	Direct · Distributors · Online/API Marketplaces
Key Sub-Regions Covered	Hyderabad · Visakhapatnam · Mumbai · Ahmedabad · Pune · Delhi NCR

Frequently Asked Questions

How fast is India empagliflozin market growing?

Demand in India is expected to expand at 33.8% CAGR by 2036 based on local demand and qualification needs.

Who leads India empagliflozin market?

Dr. Reddy’s Laboratories and MetroChem API compete through formulation access. Other local suppliers use quality evidence to gain buyer trust.

What is driving adoption in India empagliflozin market?

Diabetes demand and cardiorenal label use are expected to move buyers toward qualified empagliflozin API suppliers.

How is the empagliflozin market performing in South Korea?

A 30.9% CAGR by 2036 reflects country demand conditions and supplier qualification needs.

Country Market Snapshot Table

Parameter	Value
Market Size in 2025 (Value)	USD 22.9 million
Market Size in 2026 (Value)	USD 30.0 million
Market Forecast in 2036 (Value)	USD 443.1 million
CAGR (2026 to 2036)	30.9%
Years Considered	2021 to 2036
Base Year	2025
Forecast Period	2026 to 2036
Units Considered	Value in USD million
Leading Sub-Region	Seoul Capital Area and Incheon pharma corridors

South Korea Empagliflozin Market Outlook

South Korea is a filing-sensitive formulation market with moderate volume. IDF reported 5.0 million adults with diabetes in South Korea in 2024. Korea DMF evidence and local quality review are expected to support a 30.9% CAGR by 2036. Supplier selection should favor documentation depth over opportunistic spot supply.

Commercial demand is expected to favor audited suppliers that can support filings and repeated quality reviews. This makes documentation strength as important as synthesis scale.

Key Growth Drivers

• South Korea demand is supported by IDF data showing 5.0 million adults with diabetes in 2024.
• South Korea supplier screening gains support from Dr. Reddy’s listing Korea DMF among 7 filing routes for empagliflozin API.
• Formulators are expected to value impurity discipline as cardiorenal use widens product planning.
• Direct sourcing can work well when suppliers support local review and stable batch history.

Key Restraints

• South Korea treatment conversion can lag since WHO reported over 50% of people with diabetes did not take medication in 2022.
• Market scale gives buyers less volume leverage than China or India during API negotiations.
• Supplier access can narrow when companies lack Korea-ready filing support.

What makes South Korea unique

South Korea is unique because supplier approval depends on quality review and Korea-ready filing evidence.

Key Companies

• Hanmi Pharm
• Dong-A ST
• Daewoong Pharmaceutical
• Chong Kun Dang
• Celltrion Pharm

Sales & Marketing Channels

• Direct API contracts
• Local formulation partners
• Hospital tender routes
• Regulated distributors
• Specialty pharma channels

Country Segment Breakdown Table

Segment	Sub-Segments
By Form	Powder · Crystalline
By Purity Grade	>=99.5% · 98.0%-99.5% · <98%
By Application	Type 2 Diabetes · Heart Failure · Chronic Kidney Disease
By Sales Channel	Direct · Distributors · Online/API Marketplaces
Key Sub-Regions Covered	Seoul · Incheon · Gyeonggi · Daejeon · Busan · Daegu

Frequently Asked Questions

How fast is South Korea empagliflozin market growing?

Demand in South Korea is expected to expand at 30.9% CAGR by 2036 based on local demand and qualification needs.

Who leads South Korea empagliflozin market?

Hanmi Pharm and Dong-A ST compete through formulation access. Other local suppliers use quality evidence to gain buyer trust.

What is driving adoption in South Korea empagliflozin market?

Diabetes demand and cardiorenal label use are expected to move buyers toward qualified empagliflozin API suppliers.

What is the empagliflozin market outlook in the United States?

A 29.8% CAGR by 2036 reflects country demand conditions and supplier qualification needs.

Country Market Snapshot Table

Parameter	Value
Market Size in 2025 (Value)	USD 65.5 million
Market Size in 2026 (Value)	USD 85.0 million
Market Forecast in 2036 (Value)	USD 1153.9 million
CAGR (2026 to 2036)	29.8%
Years Considered	2021 to 2036
Base Year	2025
Forecast Period	2026 to 2036
Units Considered	Value in USD million
Leading Sub-Region	Northeast and national generic supply networks

United States Empagliflozin Market Outlook

The United States is shaped by strict filing expectations and chronic disease demand. CDC reported 40.1 million people with diagnosed or undiagnosed diabetes in 2023. FDA systems and label requirements are projected to support a 29.8% CAGR by 2036. API suppliers need USDMF depth and quick audit responses to compete.

Commercial demand is expected to favor audited suppliers that can support filings and repeated quality reviews. This makes documentation strength as important as synthesis scale.

Key Growth Drivers

• United States demand is supported by CDC data showing 40.1 million people with diabetes in 2023.
• United States cardiorenal use is supported by DailyMed labeling that lists 3 adult therapeutic pathways for Jardiance.
• FDA Orange Book checks are expected to guide buyers as generic planning moves through approval pathways.
• Formulators prefer suppliers with USDMF coverage and repeatable impurity evidence before commercial awards.

Key Restraints

• United States demand conversion is limited because CDC estimated 27.6% of adults with diabetes were undiagnosed.
• Supplier qualification can be slow because FDA-based filing evidence must be checked before commercial sourcing.
• Price pressure can rise quickly after generic competition expands across oral SGLT2 products.

What makes United States unique

The United States is unique because FDA databases and Orange Book checks shape product launch planning.

Key Companies

• Boehringer Ingelheim Pharmaceuticals
• Eli Lilly and Company
• Dr. Reddy’s Laboratories USA
• Lupin Pharmaceuticals Inc.
• Aurobindo Pharma USA

Sales & Marketing Channels

• Direct API supply
• ANDA-based formulation programs
• Contract manufacturing
• National wholesalers
• Specialty distributors

Country Segment Breakdown Table

Segment	Sub-Segments
By Form	Powder · Crystalline
By Purity Grade	>=99.5% · 98.0%-99.5% · <98%
By Application	Type 2 Diabetes · Heart Failure · Chronic Kidney Disease
By Sales Channel	Direct · Distributors · Online/API Marketplaces
Key Sub-Regions Covered	New Jersey · North Carolina · Pennsylvania · California · Texas · Illinois

Frequently Asked Questions

How fast is United States empagliflozin market growing?

Demand in United States is expected to expand at 29.8% CAGR by 2036 based on local demand and qualification needs.

Who leads United States empagliflozin market?

Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Company compete through formulation access. Other local suppliers use quality evidence to gain buyer trust.

What is driving adoption in United States empagliflozin market?

Diabetes demand and cardiorenal label use are expected to move buyers toward qualified empagliflozin API suppliers.

How is the empagliflozin market performing in Germany?

A 28.4% CAGR by 2036 reflects country demand conditions and supplier qualification needs.

Country Market Snapshot Table

Parameter	Value
Market Size in 2025 (Value)	USD 27.3 million
Market Size in 2026 (Value)	USD 35.0 million
Market Forecast in 2036 (Value)	USD 426.3 million
CAGR (2026 to 2036)	28.4%
Years Considered	2021 to 2036
Base Year	2025
Forecast Period	2026 to 2036
Units Considered	Value in USD million
Leading Sub-Region	North Rhine-Westphalia and southern pharma corridors

Germany Empagliflozin Market Outlook

Germany is a quality-led demand market with careful reimbursement review. IDF reported 6.5 million adults with diabetes in Germany in 2024. EMA and German G-BA review activity are expected to support a 28.4% CAGR by 2036. Suppliers need strong documentation before lower-cost API can win trust.

Commercial demand is expected to favor audited suppliers that can support filings and repeated quality reviews. This makes documentation strength as important as synthesis scale.

Key Growth Drivers

• Germany demand is supported by IDF data showing 6.5 million adults with diabetes in 2024.
• Germany CKD access is supported by G-BA evidence noting the chronic kidney disease indication entered force on 1 February 2024.
• German buyers are expected to reward API suppliers with stable quality systems and complete batch records.
• Pharmacy reimbursement systems can support broad use once finished-dose products meet access requirements.

Key Restraints

• Germany demand conversion can lag as WHO reported over 50% of people with diabetes did not take medication in 2022.
• Supplier qualification can slow switching because buyers require strong documentation before accepting lower-cost API.
• Reimbursement pressure can reduce finished-product margins and squeeze API pricing.

What makes Germany unique

Germany is unique because reimbursement review and strict supplier documentation both guide API qualification.

Key Companies

• Boehringer Ingelheim
• STADA Arzneimittel
• Ratiopharm
• Hexal
• Zentiva Germany

Sales & Marketing Channels

• Direct API contracts
• Generic formulation buyers
• Hospital purchasing groups
• Pharmacy wholesalers
• EU distribution partners

Country Segment Breakdown Table

Segment	Sub-Segments
By Form	Powder · Crystalline
By Purity Grade	>=99.5% · 98.0%-99.5% · <98%
By Application	Type 2 Diabetes · Heart Failure · Chronic Kidney Disease
By Sales Channel	Direct · Distributors · Online/API Marketplaces
Key Sub-Regions Covered	North Rhine-Westphalia · Bavaria · Baden-Wurttemberg · Hesse · Hamburg · Berlin

Frequently Asked Questions

How fast is Germany empagliflozin market growing?

Demand in Germany is expected to expand at 28.4% CAGR by 2036 based on local demand and qualification needs.

Who leads Germany empagliflozin market?

Boehringer Ingelheim and STADA Arzneimittel compete through formulation access. Other local suppliers use quality evidence to gain buyer trust.

What is driving adoption in Germany empagliflozin market?

Diabetes demand and cardiorenal label use are expected to move buyers toward qualified empagliflozin API suppliers.

What is the empagliflozin market forecast for France?

A 27.9% CAGR by 2036 reflects country demand conditions and supplier qualification needs.

Country Market Snapshot Table

Parameter	Value
Market Size in 2025 (Value)	USD 21.9 million
Market Size in 2026 (Value)	USD 28.0 million
Market Forecast in 2036 (Value)	USD 328.0 million
CAGR (2026 to 2036)	27.9%
Years Considered	2021 to 2036
Base Year	2025
Forecast Period	2026 to 2036
Units Considered	Value in USD million
Leading Sub-Region	Ile-de-France and Lyon pharma corridors

France Empagliflozin Market Outlook

France is guided by reimbursement review and chronic disease access. IDF reported 4.1 million adults with diabetes in France in 2024. Public benefit review and regulated formulation demand are expected to support a 27.9% CAGR by 2036. Suppliers must align API quality evidence with finished-product access needs.

Commercial demand is expected to favor audited suppliers that can support filings and repeated quality reviews. This makes documentation strength as important as synthesis scale.

Key Growth Drivers

• France demand is supported by IDF data showing 4.1 million adults with diabetes in 2024.
• France cardiorenal relevance is supported by EMA product information that states 3 therapeutic areas for Jardiance.
• French buyers are expected to connect API sourcing with finished-product reimbursement and clinical review.
• Generic suppliers can benefit when reimbursement access supports wider prescribing across chronic disease groups.

Key Restraints

• France demand conversion can lag as WHO reported over 50% of people with diabetes did not take medication in 2022.
• Pricing negotiation can narrow margin room for finished products and API sourcing.
• Suppliers without strong documentation may lose access when public review raises evidence expectations.

What makes France unique

France is unique because reimbursement review can affect both launch timing and supplier selection.

Key Companies

• Sanofi
• Servier
• Biogaran
• Zentiva France
• Bouchara-Recordati

Sales & Marketing Channels

• Direct API contracts
• Reimbursement-based formulation programs
• Hospital pharmacy buyers
• National wholesalers
• Specialty distributors

Country Segment Breakdown Table

Segment	Sub-Segments
By Form	Powder · Crystalline
By Purity Grade	>=99.5% · 98.0%-99.5% · <98%
By Application	Type 2 Diabetes · Heart Failure · Chronic Kidney Disease
By Sales Channel	Direct · Distributors · Online/API Marketplaces
Key Sub-Regions Covered	Ile-de-France · Lyon · Normandy · Hauts-de-France · Occitanie · Provence-Alpes-Cote d’Azur

Frequently Asked Questions

How fast is France empagliflozin market growing?

Demand in France is expected to expand at 27.9% CAGR by 2036 based on local demand and qualification needs.

Who leads France empagliflozin market?

Sanofi and Servier compete through formulation access. Other local suppliers use quality evidence to gain buyer trust.

What is driving adoption in France empagliflozin market?

Diabetes demand and cardiorenal label use are expected to move buyers toward qualified empagliflozin API suppliers.

What is the empagliflozin market outlook in the United Kingdom?

A 27.6% CAGR by 2036 reflects country demand conditions and supplier qualification needs.

Country Market Snapshot Table

Parameter	Value
Market Size in 2025 (Value)	USD 20.4 million
Market Size in 2026 (Value)	USD 26.0 million
Market Forecast in 2036 (Value)	USD 297.5 million
CAGR (2026 to 2036)	27.6%
Years Considered	2021 to 2036
Base Year	2025
Forecast Period	2026 to 2036
Units Considered	Value in USD million
Leading Sub-Region	London and national NHS supply pathways

United Kingdom Empagliflozin Market Outlook

The United Kingdom is shaped by NICE guidance and NHS supply pathways. IDF reported 4.5 million adults with diabetes in the United Kingdom in 2024. National guidance and chronic kidney disease use are expected to support a 27.6% CAGR by 2036. Buyers should favor suppliers that protect filing continuity.

Commercial demand is expected to favor audited suppliers that can support filings and repeated quality reviews. This makes documentation strength as important as synthesis scale.

Key Growth Drivers

• United Kingdom demand is supported by IDF data showing 4.5 million adults with diabetes in 2024.
• United Kingdom kidney disease access is supported by NICE TA942 which recommends empagliflozin for eligible adults with CKD.
• NHS supply routes are expected to favor stable formulation partners with secure API sourcing.
• National guidance can help buyers plan wider cardiorenal portfolios around one molecule.

Key Restraints

• United Kingdom demand conversion can lag as WHO reported over 50% of people with diabetes did not take medication in 2022.
• Imported API reliance can expose formulation supply to documentation and logistics delays.
• Uptake can remain budget-sensitive because NHS pathways review treatment cost before broad access.

What makes United Kingdom unique

The United Kingdom is unique because NICE guidance and NHS pathways shape demand timing.

Key Companies

• Boehringer Ingelheim UK
• Eli Lilly UK
• Accord Healthcare
• Teva UK
• Zentiva UK

Sales & Marketing Channels

• Direct API contracts
• NHS supply routes
• Generic formulation buyers
• Hospital pharmacy buyers
• National wholesalers

Country Segment Breakdown Table

Segment	Sub-Segments
By Form	Powder · Crystalline
By Purity Grade	>=99.5% · 98.0%-99.5% · <98%
By Application	Type 2 Diabetes · Heart Failure · Chronic Kidney Disease
By Sales Channel	Direct · Distributors · Online/API Marketplaces
Key Sub-Regions Covered	London · Manchester · Birmingham · Leeds · Glasgow · Cambridge

Frequently Asked Questions

How fast is United Kingdom empagliflozin market growing?

Demand in United Kingdom is expected to expand at 27.6% CAGR by 2036 based on local demand and qualification needs.

Who leads United Kingdom empagliflozin market?

Boehringer Ingelheim UK and Eli Lilly UK compete through formulation access. Other local suppliers use quality evidence to gain buyer trust.

What is driving adoption in United Kingdom empagliflozin market?

Diabetes demand and cardiorenal label use are expected to move buyers toward qualified empagliflozin API suppliers.

What is the empagliflozin market forecast for Japan?

A 25.8% CAGR by 2036 reflects country demand conditions and supplier qualification needs.

Country Market Snapshot Table

Parameter	Value
Market Size in 2025 (Value)	USD 25.4 million
Market Size in 2026 (Value)	USD 32.0 million
Market Forecast in 2036 (Value)	USD 317.7 million
CAGR (2026 to 2036)	25.8%
Years Considered	2021 to 2036
Base Year	2025
Forecast Period	2026 to 2036
Units Considered	Value in USD million
Leading Sub-Region	Tokyo and Kansai pharma corridors

Japan Empagliflozin Market Outlook

Japan combines steady oral therapy demand with careful supplier validation. IDF reported 10.8 million adults with diabetes in Japan in 2024. Quality review and long validation cycles are projected to support a 25.8% CAGR by 2036. Suppliers must show stable documents before commercial switching becomes realistic.

Commercial demand is expected to favor audited suppliers that can support filings and repeated quality reviews. This makes documentation strength as important as synthesis scale.

Key Growth Drivers

• Japan demand is supported by IDF data showing 10.8 million adults with diabetes in 2024.
• Japan cardiorenal planning is supported by EMA product information that gives a 10 mg once-daily dose for chronic kidney disease.
• Japanese formulation partners are expected to value empagliflozin where cardiorenal use supports portfolio extension.
• Direct sourcing can work well when suppliers support long validation cycles and local documentation needs.

Key Restraints

• Japan demand conversion can lag as WHO reported over 50% of people with diabetes did not take medication in 2022.
• Supplier switching can be slow because validation cycles and quality reviews take time.
• Smaller API suppliers can face access limits when documentation depth does not match buyer expectations.

What makes Japan unique

Japan is unique because supplier validation can be slower than demand growth.

Key Companies

• Nippon Boehringer Ingelheim
• Eli Lilly Japan
• Sawai Group Holdings
• Towa Pharmaceutical
• Nichi-Iko Pharmaceutical

Sales & Marketing Channels

• Direct API contracts
• Generic formulation programs
• Wholesaler networks
• Hospital pharmacy routes
• Specialty distributors

Country Segment Breakdown Table

Segment	Sub-Segments
By Form	Powder · Crystalline
By Purity Grade	>=99.5% · 98.0%-99.5% · <98%
By Application	Type 2 Diabetes · Heart Failure · Chronic Kidney Disease
By Sales Channel	Direct · Distributors · Online/API Marketplaces
Key Sub-Regions Covered	Tokyo · Osaka · Yokohama · Nagoya · Fukuoka · Sapporo

Frequently Asked Questions

How fast is Japan empagliflozin market growing?

Demand in Japan is expected to expand at 25.8% CAGR by 2036 based on local demand and qualification needs.

Who leads Japan empagliflozin market?

Nippon Boehringer Ingelheim and Eli Lilly Japan compete through formulation access. Other local suppliers use quality evidence to gain buyer trust.

What is driving adoption in Japan empagliflozin market?

Diabetes demand and cardiorenal label use are expected to move buyers toward qualified empagliflozin API suppliers.

Who are the leading companies in the empagliflozin market?

Dr. Reddy’s Laboratories and MetroChem API lead the API-side evidence. MSN Laboratories, Lupin and Boehringer Ingelheim support formulation and brand activity.

• DMF coverage and consistent impurity profiles create a competitive advantage for API manufacturers seeking regulated-market business.
• Rising use of Empagliflozin across diabetes and cardiorenal therapies improves demand visibility for formulation companies.
• Growing documentation and batch-planning requirements create support opportunities for contract manufacturing organizations (CMOs).
• Fast audit responses and strong product documentation help regulated-market suppliers differentiate themselves from competitors.

Industry in the competition is shaped by documentation strength. Dr. Reddy’s lists empagliflozin API with USDMF and Korea DMF coverage. MetroChem API has official CDSCO written confirmation evidence for Empagliflozin IHS. This supports buyer confidence in CMO and CDMO services where filings depend on supplier evidence.

Formulation-side competition is influenced by product access and brand transfers. Lupin’s December 2024 acquisition of GIBTULIO and related diabetes trademarks strengthens its India diabetes portfolio. MSN Laboratories also lists empagliflozin tablet products. These signals matter because API offtake follows finished-dose planning.

Suppliers with stronger filing support are better positioned than companies selling only on spot price. The opportunity is clearest for firms that combine synthesis control with high-potent oral solid dosage contract manufacturing support and stable quality systems.

How do top empagliflozin companies compare?

Dr. Reddy’s and MetroChem show stronger public API evidence while Lupin and MSN support formulation-side demand signals.

Company	Relevance to Market Title	API Evidence	Formulation Evidence	Regulatory Filing Depth	Geographic Footprint
Dr. Reddy’s Laboratories	Very High	Very Strong	Moderate	Very Strong	Global
MetroChem API	Very High	Very Strong	Low	Strong	India and export markets
MSN Laboratories	High	Moderate	Strong	Moderate	India and selected exports
Lupin	High	Low	Strong	Strong	India and global generics
Boehringer Ingelheim	High	Low	Very Strong	Very Strong	Global
Eli Lilly and Company	Moderate	Low	Strong	Very Strong	United States and global
Zydus Lifesciences	Moderate	Moderate	Moderate	Moderate	India and export markets
Aurobindo Pharma	Moderate	Moderate	Moderate	Moderate	India and global generics
Sawai Group Holdings	Moderate	Low	Moderate	Moderate	Japan
STADA Arzneimittel	Moderate	Low	Moderate	Moderate	Europe

Source: Future Market Insights competitive analysis, 2026.

Who are the key players in the empagliflozin market?

Dr. Reddy’s Laboratories, MetroChem API and MSN Laboratories are listed with Lupin and Boehringer Ingelheim among other suppliers.

Key global companies leading the empagliflozin market include:

• Dr. Reddy’s Laboratories
• MetroChem API
• MSN Laboratories
• Lupin
• Boehringer Ingelheim
• Eli Lilly and Company
• Zydus Lifesciences
• Aurobindo Pharma
• Sawai Group Holdings
• STADA Arzneimittel

Key Developments in Empagliflozin Market

• In April 2025 IDF released its Diabetes Atlas 11th edition with 589 million adults living with diabetes worldwide.
• In September 2025 CDSCO issued written confirmation for MetroChem API Unit-IV covering Empagliflozin IHS manufacturing and packing.
• In December 2024 Lupin announced the acquisition of GIBTULIO and related anti-diabetes trademarks from Boehringer Ingelheim.

Key Players in the Empagliflozin Market

API Manufacturers

• Dr. Reddy’s Laboratories
• MetroChem API
• Zydus Lifesciences
• Aurobindo Pharma
• Hetero Labs

Formulation and Brand Owners

• Boehringer Ingelheim
• Eli Lilly and Company
• Lupin
• MSN Laboratories
• Sawai Group Holdings

Regional Generic Suppliers

• STADA Arzneimittel
• Accord Healthcare
• Teva UK
• Zentiva
• Biogaran

Empagliflozin Market - Report Scope

Parameter	Details
Forecast period	2026 to 2036
Historical period	2021 to 2025
Quantitative unit	Revenue in USD billion
By form	Powder and crystalline
By purity grade	>=99.5%; 98.0%-99.5%; <98%
By application	Type 2 diabetes; heart failure; chronic kidney disease
By sales channel	Direct; distributors; online/API marketplaces
Regions covered	North America; Latin America; Europe; East Asia; South Asia and Pacific; Middle East and Africa
Countries covered	China; India; South Korea; United States; Germany; France; United Kingdom; Japan
Key companies profiled	Dr. Reddy’s; MetroChem API; MSN Laboratories; Lupin; Boehringer Ingelheim; Eli Lilly

Empagliflozin Market - Scope & Definition

Attribute	Detail
Market Definition	Commercially traded empagliflozin active pharmaceutical ingredient used in oral solid dosage medicines.
Functions Covered	Glucose-lowering API supply; cardiorenal product support; regulated formulation input; filing-backed active ingredient sourcing.
Applications Covered	Type 2 diabetes; heart failure; chronic kidney disease across approved empagliflozin product pathways.
End-Use Industries	Pharmaceutical manufacturing; generic formulation; contract development and manufacturing; regulated API distribution.
Grades Covered	>=99.5%; 98.0%-99.5%; <98% purity grades.
Inclusions	Powder and crystalline empagliflozin API sold through direct contracts and distributors. Online/API marketplaces are included for early sourcing.
Exclusions	Finished Jardiance revenue; combination brand revenue; non-empagliflozin SGLT2 APIs; GLP-1 drugs; insulin; excipients; packaging; pharmacy dispensing revenue.

Empagliflozin Market - Research Methodology

Method	Description
Primary Research	FMI analyst interviews with API buyers and formulation manufacturers. Regulatory consultants and distribution partners were also reviewed.
Desk Research	Review of FDA and EMA records. DailyMed and CDSCO records were also checked. Company portfolios and public medicine records were reviewed separately.
Market Sizing & Forecasting	Bottom-up API demand approach using application mix and channel share. Contract pricing and country-level formulation activity were then reconciled.
Data Validation	Cross-verification using approved-use evidence and disease burden indicators. Company portfolio evidence and regional API supply behavior were then checked.

Empagliflozin Market Breakdown by Core Segments

Empagliflozin Market Segmented by Form:

• Powder
• Crystalline

Empagliflozin Market Segmented by Purity Grade:

• >=99.5%
• 98.0%-99.5%
• <98%

Empagliflozin Market Segmented by Application:

• Type 2 Diabetes
• Heart Failure
• Chronic Kidney Disease

Empagliflozin Market Segmented by Sales Channel:

• Direct
• Distributors
• Online/API Marketplaces

Empagliflozin Market by Region:

• North America
• Latin America
• Europe
• East Asia
• South Asia and Pacific
• Middle East and Africa

Research Sources and Bibliography

• Centers for Disease Control and Prevention. (2026, January 21). National diabetes statistics report.
• Central Drugs Standard Control Organisation. (2025, September 26). Written confirmation for MetroChem API Private Limited Unit-IV.
• DailyMed. (2026). Jardiance - empagliflozin tablet film coated.
• Dr. Reddy’s Laboratories. (2026). About Empagliflozin API.
• European Medicines Agency. (2026, February). Jardiance product information.
• European Medicines Agency. (2024). Jardiance EPAR summary for the public.
• Federal Joint Committee. (2024, February 1). Empagliflozin new therapeutic indication chronic kidney disease.
• International Diabetes Federation. (2025, April 7). Over 250 million people worldwide unaware they have diabetes according to new IDF research.
• International Diabetes Federation. (2025). Diabetes Atlas 11th edition.
• International Diabetes Federation. (2025). China diabetes country report 2000-2050.
• International Diabetes Federation. (2025). India diabetes country report 2000-2050.
• International Diabetes Federation. (2025). Republic of Korea diabetes country report 2000-2050.
• International Diabetes Federation. (2025). Germany diabetes country report 2000-2050.
• International Diabetes Federation. (2025). France diabetes country report 2000-2050.
• International Diabetes Federation. (2025). United Kingdom diabetes country report 2000-2050.
• International Diabetes Federation. (2025). Japan diabetes country report 2000-2050.
• Lupin Limited. (2024, December 13). Lupin acquires 3 trademarks from Boehringer Ingelheim to strengthen diabetes portfolio.
• MSN Laboratories. (2025). Rx list for Empaone 10 and 25 empagliflozin tablets.
• National Institute for Health and Care Excellence. (2023, December 20). Empagliflozin for treating chronic kidney disease.
• U.S. Food and Drug Administration. (2026, May 8). Approved drug products with therapeutic equivalence evaluations Orange Book.
• World Health Organization. (2024, November 14). Diabetes fact sheet.

This bibliography is provided for reader reference and is not exhaustive. The full report contains the complete reference list and detailed citations.

This Report Answers

• Market size estimates for 2026 and forecasts through 2036 for the empagliflozin market.
• Insights across regional and country-level markets with country CAGR comparison.
• Analysis of demand drivers and buyer qualification needs. API sourcing behavior is reviewed separately.
• Evaluation of leading forms and purity grades across regulated formulation demand.
• Assessment of diabetes and heart failure applications. Chronic kidney disease demand is reviewed separately.
• Identification of opportunities across direct sales and distributor channels.
• Evaluation of supplier documentation and impurity control. Audit readiness is reviewed as a separate buyer filter.
• Country-level analysis covering China and India. South Korea and the United States are included. Germany and France are also covered. The United Kingdom and Japan complete the country view.
• Assessment of the competitive landscape including API manufacturers and formulation companies.
• Delivery of market data and forecasts. Supporting analysis is prepared in Word and Excel-ready formats.